launch partner programs. We exceeded our state engagement goals in 2025, expanding discussions 13 states, and met our goal of engaging in now two live partner programs. We expect these partner programs to play a critical role in shaping policy, validating economics

May 27, 2026 / receipt

Operating expenses for the quarter were $9 million, down from $9.4 million for the prior year period, reflecting our continued disciplined expense management. Research and development expenses were $3.2 million compared to $3.1 million in 2024. With the completion of the prime study, R&D expenses will likely decrease as we focus resources on activities that support commercialization and awareness building. Selling general and administrative expenses were $5.7 million versus $6.3 million in the prior year, reflecting our prudent allocation to targeted commercial initiatives and strategic headcount.

Mar 18, 2026 / receipt, needs a key / Austin Ertz, CFO | earnings call 2026-03-18 | transcript d4bea8bb-d4c4-4b25-ba93-bd585ce3bee5 | chars 15024-15628 | segment 14

Another is our work on a product to provide a more accurate estimate of when a baby will arrive to help a mother in planning maternity leave, travel, and other important milestones.

Nov 8, 2023 / receipt, needs a key / Xenia Lingard, CEO | earnings call 2023-11-08 | transcript 5f074219-4577-4f2f-bd83-509d841e8479 | chars 3348-3529 | segment 3

Actively Engaged in 6 States

ir_statement / Sep 15, 2026 / receipt

Geographic adjacency enables efficient sales and field coverage

ir_statement / Sep 15, 2026 / receipt

Prioritizing certain states to drive early volume, strengthen reimbursement positioning, and enable scalable commercialization

ir_statement / Sep 15, 2026 / receipt

Medicaid Pilot Expansions

ir_statement / Sep 15, 2026 / receipt

✓Reduced healthcare costs through improvements in the health of the baby and reducing the need for the NICU

ir_statement / Sep 8, 2026 / receipt

Broad sample collection across U.S. population

ir_statement / Sep 8, 2026 / receipt

▪Engaged with all tier 1 &

ir_statement / Sep 8, 2026 / receipt

▪Ongoing conversations with payers in all targeted states

ir_statement / Sep 8, 2026 / receipt

As we build toward formal guidelines, our focus is on securing access to the PreTRM Test by partnering with key stakeholders in local ecosystem

ir_statement / Sep 8, 2026 / receipt

Actively Engaged in 6 States Accounting for 33% of US Births

ir_statement / Sep 8, 2026 / receipt

Focusing on 1st and 2nd Wave States Covering ~50% of US Births

ir_statement / Sep 8, 2026 / receipt

Geographic adjacency enables efficient sales and field coverage

ir_statement / Sep 8, 2026 / receipt